Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX

Core Viewpoint - A class action securities lawsuit has been filed against Kyverna Therapeutics, Inc. alleging false statements and omissions related to its initial public offering (IPO) [1][2]. Group 1: Lawsuit Details - The complaint claims that the defendants made false statements regarding the IPO strategy, terms, and disclosures in the Offering Documents [2]. - It is alleged that the underwriter defendants should have been aware of Kyverna's undisclosed issues due to ongoing communications with the company's management and legal team [2]. Group 2: Class Definition and Participation - The lawsuit aims to recover losses for investors who purchased Kyverna common stock linked to the company's February 2024 IPO [4]. - Investors affected by the alleged securities fraud can participate without incurring out-of-pocket costs [3]. Group 3: Next Steps for Investors - Investors who suffered losses in Kyverna Therapeutics have until February 7, 2025, to request to be appointed as lead plaintiff [5]. Group 4: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [6].